The final, formatted version of the article will be published soon.
STUDY PROTOCOL article
Front. Oncol.
Sec. Breast Cancer
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1427046
This article is part of the Research Topic Promotion of Quality of Life in Oncology Patients And Survivors Through Physical Activity View all 3 articles
Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy (THRIVE) Trial: A Study Protocol
Provisionally accepted- 1 Department of Exercise and Health Sciences, University of Massachusetts Boston, Boston, United States
- 2 Department of Medical Oncology, Dana–Farber Cancer Institute, Boston, Massachusetts, United States
- 3 Department of Nursing, University of Massachusetts Boston, Boston, United States
Background: Higher rates of physical inactivity and comorbid conditions are reported in Hispanic/Latinx and Black cancer patients receiving chemotherapy compared to their White counterparts. Despite the beneficial effect of exercise training for cancer patients, rates of participation in exercise oncology clinical trials are low among disadvantaged and racial and ethnic minority groups. Here, we will examine the effect of an exercise intervention using a novel, accessible, and cost-effective home-based exercise approach among Hispanic/Latinx and Black cancer patients receiving chemotherapy on exercise participation and cardiovascular disease risk. Methods: The THRIVE trial is an 8-month prospective, three-arm study of 45 patients who are randomized in a 1:1:1 fashion to a supervised exercise intervention (SUP), unsupervised exercise (UNSUP), or an attention control (AC) group. Eligible patients include those with breast, colorectal, or prostate cancer, who are sedentary, overweight or obese, self-identify as Hispanic/Latinx or Black, and plan to receive chemotherapy. Patients randomized to the SUP group participate in a home-based 16-week periodized aerobic and resistance exercise program performed three days per week, supervised through video conference technology. Patients randomized to the UNSUP group participate in an unsupervised 16-week, telehealth-based, periodized aerobic and resistance exercise program performed three days per week using the same exercise prescription parameters as the SUP group. Patients randomized to the AC group receive a 16-week home-based stretching program. The primary outcome is changes in minutes of physical activity assessed by 7-day accelerometry at post-intervention. Secondary outcomes include cardiovascular risk factors, patient-reported outcomes, and physical function. Outcome measures are tested at baseline, post-intervention at month 4, and after a non-intervention follow-up period at month 8. Discussion: The THRIVE trial is the first study to employ a novel and potentially achievable exercise intervention for a minority population receiving chemotherapy. In addition, this study utilizes an intervention approach to investigate the biological and behavioral mechanisms underlying exercise participation in these cancer patients. Results will guide and inform large randomized controlled trials to test the effect of home-based exercise on treatment outcomes and comorbid disease risk in minority patients with cancer undergoing chemotherapy. Clinical Trial Registration: https://classic.clinicaltrials.gov/ct2/show/NCT05327452 identifier [NCT#05327452].
Keywords: Cancer, Racial and ethnic minorities, home-based exercise, Exercise participation, cardiovascular risk factors
Received: 04 Jun 2024; Accepted: 23 Aug 2024.
Copyright: © 2024 Yan, Gonzalo-Encabo, Wilson, Christopher, Cannon, Kang, Gardiner, Perez, Norris, Gundersen, Hayman, Freedman, Rebbeck, Shi and Dieli-Conwright. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Christina Dieli-Conwright, Department of Medical Oncology, Dana–Farber Cancer Institute, Boston, 02215, Massachusetts, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.